In this first of two podcasts, expert faculty review the latest data on the management of advanced urothelial cancer with novel therapies including immune checkpoint inhibitors and antibody-drug conjugates. This activity is available for CE/CME credit. Claim your credit at <a href="pce.is/GIGU" target="_blank">pce.is/GIGU</a>.Contributors:Arjun Balar, MDTerran W. Sims, MSN, ACNP-C, CNN-BC, COCNDr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.Ms Sims: consulting fees: Coloplast.

Advanced Urothelial Cancer: Applying New Therapeutic Options, Part 2

Practicing Clinicians Exchange keeps advanced practice providers up to date with timely interviews from the front lines on current advances and best practices in medicine. Many of the podcasts are available for CE/CME credit.